Posted by Michael Wonder on 25 Jan 2017
AbbVie initiates phase 2 clinical trial programs for ABBV-8E12, an investigational anti-tau antibody, in early Alzheimer's disease and progressive supranuclear palsy
25 February 2017 - ABBV-8E12 granted fast track designation from the U.S. FDA for progressive supranuclear palsy.
AbbVie announced the start of two Phase 2 clinical trial programs to evaluate ABBV-8E12, an investigational anti-tau antibody, in patients with early Alzheimer's disease and progressive supranuclear palsy (PSP).
In recognition of the lack of treatment options available to patients with PSP, the U.S. FDA granted fast track designation to ABBV-8E12. The FDA and EMA also granted orphan drug designations to ABBV-8E12 for PSP.
